522 related articles for article (PubMed ID: 17024154)
21. [Management of prolactinomas: what's new in 2010?].
Sedda A; Meyer P
Rev Med Suisse; 2011 Jan; 7(277):20-4. PubMed ID: 21309169
[TBL] [Abstract][Full Text] [Related]
22. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
[TBL] [Abstract][Full Text] [Related]
23. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
24. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
[TBL] [Abstract][Full Text] [Related]
25. Current treatment issues in female hyperprolactinaemia.
Crosignani PG
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):152-64. PubMed ID: 16288952
[TBL] [Abstract][Full Text] [Related]
26. Management of Dopamine Agonist-Resistant Prolactinoma.
Maiter D
Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
[TBL] [Abstract][Full Text] [Related]
27. Prolactinomas in children and adolescents--consequences in adult life.
Duntas LH
J Pediatr Endocrinol Metab; 2001; 14 Suppl 5():1227-32; discussion 1261-2. PubMed ID: 11964017
[TBL] [Abstract][Full Text] [Related]
28. Prolactin excess: treatment and toxicity.
Gillam MP; Fideleff H; Boquete HR; Molitch ME
Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():108-14. PubMed ID: 16456489
[TBL] [Abstract][Full Text] [Related]
29. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
Ono M; Miki N; Kawamata T; Makino R; Amano K; Seki T; Kubo O; Hori T; Takano K
J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
[TBL] [Abstract][Full Text] [Related]
30. Medically treated prolactin-secreting pituitary adenomas: when should we operate?
Vale FL; Deukmedjian AR; Hann S; Shah V; Morrison AD
Br J Neurosurg; 2013 Feb; 27(1):56-62. PubMed ID: 22938595
[TBL] [Abstract][Full Text] [Related]
31. Non-surgical management of cystic prolactinomas.
Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
[TBL] [Abstract][Full Text] [Related]
32. [Medical treatment of prolactin and growth hormone-secreting pituitary tumors].
Jadresic A
Rev Med Chil; 1997 Nov; 125(11):1383-8. PubMed ID: 9609063
[TBL] [Abstract][Full Text] [Related]
33. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
34. Giant prolactinomas: the therapeutic approach.
Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
[TBL] [Abstract][Full Text] [Related]
35. Prolactinomas and resistance to dopamine agonists.
Brue T; Pellegrini I; Priou A; Morange I; Jaquet P
Horm Res; 1992; 38(1-2):84-9. PubMed ID: 1306523
[TBL] [Abstract][Full Text] [Related]
36. [Results of treatment for male prolactinomas].
Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
[TBL] [Abstract][Full Text] [Related]
37. [Medical treatment of prolactinoma. Quo usque tandem..].
Elsässer Imboden PN; Gomez F
Rev Med Suisse; 2005 Feb; 1(6):440-5. PubMed ID: 15786649
[TBL] [Abstract][Full Text] [Related]
38. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
[TBL] [Abstract][Full Text] [Related]
39. [Prolactinoma].
Krysiak R; Okopień B; Marek B; Szkróbka W
Przegl Lek; 2009; 66(4):198-205. PubMed ID: 19708510
[TBL] [Abstract][Full Text] [Related]
40. Dopamine agonists and valvular heart disease.
Cheung D; Heaney A
Curr Opin Endocrinol Diabetes Obes; 2009 Aug; 16(4):316-20. PubMed ID: 19506475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
